Targeted delivery of growth factors by HSV-mediated gene transfer for peripheral neuropathy.
Level 5 - mechanism / opinion, no new human data
Narrative review / preclinical summary with no human clinical data
PubMed 24369058 · doi:10.2174/156652321305131212123237
What was done
This paper summarizes preclinical approaches using non-replicating herpes simplex virus (HSV)-based vectors injected into the skin to achieve targeted delivery of neurotrophic growth factors to dorsal root ganglion (DRG) primary sensory neurons for the treatment of peripheral neuropathies.
What was found
The abstract reports no quantitative values or statistical data. It reports qualitatively that preclinical studies with non-replicating HSV-based vectors demonstrated efficacy in preventing the progression of sensory neuropathy without causing systemic side effects.
Why it matters
Delivering neurotrophic factors directly to primary sensory neurons via HSV vectors addresses the challenge of treating widespread, relatively inaccessible sensory nerves while minimizing systemic toxicity.
Limits
The abstract describes only preclinical work and provides no human clinical data. It lacks specific quantitative measurements, animal model details, sample sizes, vector constructs, or long-term durability and safety metrics.
Cited by
- supports Approximately 20 million individuals in the United States suffer from peripheral neuropathy.